The adjuvant combination of pembrolizumab (Keytruda) and belzutifan (Welireg) significantly improved disease-free survival (DFS) in patients with clear cell renal cell carcinoma (ccRCC) after nephrectomy versus pembrolizumab plus placebo[3][4]. These are the results of the 3rd phase of the LITESPARK-022 study (NCT05239728) with a total of 1800 patients[1][4][6]. This combination is the first to demonstrate better DFS compared to pembrolizumab monotherapy in the adjuvant setting[3][4]. The study included patients with intermediate-high risk, high risk, or M1 with no evidence of disease after nephrectomy[1][3]. The primary endpoint was DFS, secondary overall survival (OS), which will continue to be evaluated[3][4]. The safety profile of the combination is consistent with previous studies[3]. Merck plans to present the results at a medical congress and discuss them with regulatory authorities[3][4].